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Abstract
Background:  RHOGTPases play a significant role in modulating myometrial contractility in
uterine smooth muscle. They are regulated by at least three families of proteins, RHO guanine
nucleotide exchange factors (RHOGEFs), RHOGTPase-activating proteins (RHOGAPs) and RHO
guanine nucleotide inhibitors (RHOGDIs). RHOGEFs activate RHOGTPases from the inactive
GDP-bound to the active GTP-bound form. RHOGAPs deactivate RHOGTPases by accelerating
the intrinsic GTPase activity of the RHOGTPases, converting them from the active to the inactive
form. RHOGDIs bind to GDP-bound RHOGTPases and sequester them in the cytosol, thereby
inhibiting their activity. Ezrin-Radixin-Moesin (ERM) proteins regulate the cortical actin
cytoskeleton, and an ERM protein, moesin (MSN), is activated by and can also activate
RHOGTPases.
Methods:  We therefore investigated the expression of various RHOGEFs, RHOGAPs, a
RHOGDI and MSN in human myometrium, by semi-quantitative reverse transcription PCR, real-
time fluorescence RT-PCR, western blotting and immunofluorescence microscopy. Expression of
these molecules was also examined in myometrial smooth muscle cells.
Results:  ARHGEF1, ARHGEF11, ARHGEF12, ARHGAP5, ARHGAP24, ARHGDIA and MSN
mRNA and protein expression was confirmed in human myometrium at term pregnancy, at labour
and in the non-pregnant state. Furthermore, their expression was detected in myometrial smooth
muscle cells. It was determined that ARHGAP24 mRNA expression significantly increased at labour
in comparison to the non-labour state.
Conclusion: This study demonstrated for the first time the expression of the RHOGTPase
regulators ARHGEF1, ARHGEF11, ARHGEF12, ARHGAP5, ARHGAP24, ARHGDIA and MSN in
human myometrium, at term pregnancy, at labour, in the non-pregnant state and also in myometrial
smooth muscle cells. ARHGAP24 mRNA expression significantly increased at labour in comparison
to the non-labouring state. Further investigation of these molecules may enable us to further our
knowledge of RHOGTPase regulation in human myometrium during pregnancy and labour.
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Background
Myometrial smooth muscle contractility is regulated by
both intracellular calcium concentration ([Ca2+]i) and by
the calcium sensitivity of myofilaments [1]. Calcium sen-
sitisation refers to an increase in smooth muscle tension
and/or phosphorylation of MLC at a constant [Ca2+]i by
inhibition of myosin light chain phosphatase (MLCP).
RHOA, a member of the RHOGTPase subfamily, the RAS
family of G proteins, is the upstream component along
with two target proteins, RHO-associated coil-forming
kinase (ROCKI) and its isoform, ROCK2, which are asso-
ciated with inhibition of MLCP [2]. The RHO family of
small GTPases consists of at least 20 members which
includes RHO, RAC, CDC42 and RND [3]. RHOA mRNA
expression increased in human labouring myometrium
while active RHOA levels increased in pregnancy and
spontaneous preterm labour myometrium [4,5]. RHOB
mRNA and RND2 and 3 protein expression increased dur-
ing pregnancy while RHOD protein levels decreased at
labour, in comparison to the non-pregnant state [5,6].
RHOGTPases are highly regulated, they cycle between an
active GTP-bound and an inactive GDP-bound state and
this cycling is regulated by at least three distinct protein
families: RHOGTPase guanine nucleotide exchange fac-
tors (GEFs), RHO activating proteins (GAPs) and RHO
guanine nucleotide dissociation inhibitors (GDIs) [7-9].
RHOGEFs activate RHOGTPases by catalysing GTP for
GDP exchange. They contain a Dbl homology domain
which is responsible for the catalysis of GDP to GTP and
a pleckstrin homology domain which mediates mem-
brane localisation [10]. Some 70 RHOGEFs have been
identified in the human geneome [10]. ARHGEF1, (also
known as p115-RHOGEF), ARHGEF11 (PDZ-RHOGEF)
and ARHGEF12 (LARG) are members of a subgroup of
RHOGEFs, known as regulators of G protein signalling
(RGS) domain containing RHOGEFs. The RGS domain
mediates their binding to and activation of Gα12/13 (and
Gq also in the case of ARHGEF12), in response to G-pro-
tein coupled receptor activation [11,12]. All three exhibit
very selective activation of RHOA [13]. Moreover,
ARHGEF11 induces calcium sensitisation in the absence
of agonist mediated signalling in rabbit pulmonary artery
smooth muscle [14], its expression being up-regulated by
estradiol treatment in guinea pig myometrium [15].
RHOGAPs accelerate the low intrinsic GTP hydrolysis rate
of most RHO family members, converting the proteins to
the GDP-bound inactive conformation [16]. RHOGAPs
share a related 140 amino acid domain, that interacts with
the GTP-binding core of RHOGTPases [8]. Over 70
RHOGAPs have been identified in eucaryotes [17].
ARHGAP24 (also known as p73-RHOGAP, FilGAP or RC-
GAP72) is a filamin A-binding RHOGTPase-activating
protein involved in cell polarity, cell morphology and
cytoskeletal organisation and is also a key angiogenic reg-
ulator [18-20]. ARHGAP24 acts a specific GTPase activator
for RAC, it controls actin remodelling by inactivating
RAC, downstream of Rho, which suppresses leading edge
protrusion and promotes cell retraction to achieve cell
polarity [19]. ARHGAP5 (p190B-RHOGAP) is ubiqui-
tously expressed and has in vitro specificity for RHOA,
RAC and CDC42 [8]. Inhibition of contractility in rat vas-
cular SMCs is associated with recruitment and accumula-
tion of its isoform, p190-RHOGAP, and its subsequent
inactivation of RHOA [21,22].
RHOGDIs bind to RHOGTPases, which are prenylated,
and sequester them in the cytosol, thereby inhibiting their
activity [9]. There are three mammalian RHO family-spe-
cific GDIs, ARHGDIA (also known as RHOGDIα,
RHOGDI or RHOGDI 1), RHOGDIβ and RHOGDIγ.
ARHGDIA binds to RHOA and B, RAC1 and 2, and
CDC42 both in vitro and in vivo. In addition to their role
in the inhibition of RHOGTPases RHOGDIs may also act
as positive regulators for the targetting and regulation of
RHO activities [23].
Moesin (membrane-organizing extension spike protein,
MSN) is an ERM (Ezrin-Radixin-Moesin) regulatory pro-
tein and member of the 4.1 super-family [24]. ERM pro-
teins cross-link cortical actin filaments with the plasma
membrane and are involved in the formation of micro-
villi, cell-cell adhesion, maintenance of cell shape and
motility, and membrane trafficking [25]. MSN activation
is achieved through phosphorylation on Thr558 by ROCK2
[26]. Modulation of ERM protein activity can also contrib-
ute to GTPase activation, the conserved N-terminal FERM
domain of ERM proteins can bind to RHOGDI and dis-
place it from RHOA, RAC1 and CDC42 [27]. Further-
more, it was observed that interaction of MSN with
RHOGDI resulted in RHOA activation [28].
As the role of RHOGTPases in myometrial contractility
continues to be elucidated, regulation of these important
proteins is essential, particularly during labour. Our study
aimed to investigate the expression of ARHGEF1,
ARHGEF11, ARHGEF12, ARHGAP5, ARHGAP24, ARHG-
DIA and MSN in the human myometrium utilising RT-
PCR, western blotting and immunofluorescence tech-
niques.
Methods
Tissue collection
Biopsies of human myometrial tissue during pregnancy
were obtained at elective (pregnant not in labour, PNL)
and intrapartum (pregnant in labour, PL) and preterm
emergency caesarean delivery (prior to 34 weeks, PT). The
biopsies were excised from the upper lip of the lower uter-
ine segment incision in the midline, i.e. the upper portionReproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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of the lower uterine segment. Biopsies of human non-
pregnant myometrial tissue (non-pregnant, NP) were
obtained from pre-menopausal hysterectomy specimens
and women receiving therapy with progestagens, luteinis-
ing hormone-releasing hormone analogues, or steroid
based medications were excluded from the study. Women
who had received prostaglandins or oxytocin for either
induction or augmentation of labor were excluded from
the study. Women with gynaecologic malignancy were
also excluded from the study. Myometrial samples were
carefully dissected to minimize decidual inclusion. Ethi-
cal Committee approval for the tissue collection proce-
dure was obtained from the Research Ethics Committee
University College Hospital, Galway and recruitment was
by written informed consent. Immediately upon collec-
tion, tissue was rinsed in normal saline for myometrial
cell isolation or snap-frozen in liquid nitrogen, and stored
at -80°C.
Tissue samples for semi-quantitative RT-PCR
Myometrial biopsies were obtained at hysterectomy (n =
1), elective (n = 2) and intrapartum caesarean section (n =
2). The reason for hysterectomy was menorrhagia, aged
45. The reasons for elective caesarean section included
previous caesarean section (n = 2). The reasons for emer-
gency caesarean section were face presentation (n = 2).
The mean age of the caesarean section women was 38.5
years (range, 36–41) and all the caesarean sections were
multigravida and delivered between 37 and 39 weeks' ges-
tation.
Tissue samples for real-time fluorescence RT-PCR
For real-time RT-PCR confirmation analysis, biopsies of
myometrium were obtained at the time of elective (n = 7)
and intrapartum (n = 7) caesarean section. The reasons for
elective caesarean section included previous caesarean
section (n = 6) and placenta praevia (n = 1). The reasons
for emergency caesarean section were face presentation (n
= 4), non-reassuring foetal testing (n = 1) and previous
classical caesarean section (n = 2). The mean age of each
group was PNL, 34.4 and PL, 34.3 and the overall mean
age was 34.35 years (range, 29–41), 3 of whom were pri-
magravida and 11 multigravida. All women were deliv-
ered between 37 and 41 weeks' gestation.
Tissue samples for protein expression
Biopsies of myometrium (for the RHOGEF GAP and GDI
tissue westerns) during pregnancy were obtained at elec-
tive (n = 4) and intrapartum (n = 4) caesarean section and
at hysterectomy (n = 4). The reasons for elective caesarean
section were previous caesarean sections (n = 4). The rea-
sons for emergency caesarean delivery were non-reassur-
ing foetal testing (n = 2), face presentation (n = 1) and
previous classical caesarean section (n = 1). The mean age
of the women was 33 years (range 31–37), 4 were prima-
gravida and 4 were multigravida. All women were deliv-
ered between 39 and 40 weeks' gestation. The
hysterectomies were pre-menopausal (n = 4) with a mean
age of 46.
Biopsies of myometrium during pregnancy for the first
moesin western blots, were obtained at elective (n = 3)
and intrapartum (n = 3) caesarean section. The reasons for
elective caesarean section included maternal request (n =
1) and previous caesarean section (n = 2). The reasons for
emergency caesarean delivery were non-reassuring foetal
testing (n = 1), failed induction (n = 1) and failure to
progress (n = 1). The mean age of the women was 35.5
years (range 30–41), 3 were primagravida and 3 were mul-
tigravida. All women were delivered between 39 and 40
weeks' gestation.
Biopsies of myometrium for the last set of moesin western
blots, during pregnancy were obtained at intrapartum (n
= 3) and preterm (n = 3) caesarean sections. The reasons
for emergency caesarean delivery were non-reassuring foe-
tal testing (n = 2) and undiagnosed breech birth (n = 1).
The reasons for preterm birth were HELLP syndrome (n =
1), foetal abnormality (n = 1) and ulcerative colitis (n = 1).
The mean age of the women was 35.5 years (range,
29–37) of which 2 were primagravida and 2 were multi-
gravida. The preterm women were delivered at 32 weeks
gestation. The elective and emergency caesarean sections
were delivered between 39 and 41 weeks gestation.
Myometrial cell isolation and cell culture
Myometrial tissue samples were minced (finely with any
fibrous tissue removed) and digested in sterile filtered
Dulbecco's Modified Eagle Medium (DMEM) (minus calf
serum) (Sigma-Aldrich, Ireland) containing collagenase
type IA (Sigma-Aldrich, Ireland), collagenase type XI
(Sigma-Aldrich, Ireland) and 0.1% bovine serum albumin
(w/v) (BSA) (Sigma-Aldrich, Ireland) for 45 minutes. The
resulting suspension was vortexed and the non-dispersed
tissue fragments were separated by filtration of the mix-
ture through sterile gauze layers. Individual cells were
then collected by centrifugation at 400 g for 10 minutes.
Cells were then washed and centrifuged 2 to 3 times in
sterile 1X phosphate-buffered saline (PBS). After washing,
cells were cultured in SGM-2 medium (Cambrex, Biowhit-
taker UK Ltd., Berkshire, UK) at 37°C and 5% CO2. Cells
were sub-cultivated with trypsin/ethylenediamine-
tetraacetic acid (EDTA) at a 1:2 or 1:3 split after reaching
confluence. Myometrial cells used in experiments were
used to passage 8.
Myometrial smooth muscle cells were characterised for
mRNA expression of calponin, and estrogen receptor α
and for SM α-actin mRNA and protein expression.Reproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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RNA extraction and reverse transcription
Total RNA was isolated from myometrial tissue using TRI-
zol reagent (Life Technologies Ltd., UK) [29] and from
myometrial smooth muscle cells using the RNeasy mini
RNA isolation kit (Qiagen, Crawley, West Sussex, UK). All
RNA samples were DNase I treated using the DNA-free™
kit (Ambion, Spitfire Close, Huntingdon, Cambridge-
shire, UK). RNA (500 ng – DNase I treated) was reverse
transcribed into complementary DNA (cDNA) for use as a
template for Polymerase Chain Reaction (PCR). The RNA
samples were then denatured at 65°C for 10 minutes.
Reverse transcription was performed at 42°C for 60 min-
utes in a reaction volume of 20 μl containing the follow-
ing: oligo dT primer (500 ng), Moloney murine
leukaemia virus (M-MLV) reverse transcription buffer (50
mol l-3 Tris-HCl, pH 8.3, 75 mol l-3 KCl, 3 mol l-3 MgCl2,
10 mol l-3 dithiothreitol (DTT)) (Promega, Southampton
Science Park, Southampton, UK), diethylpyrocarbonate
(DEPC) treated water (BDH, UK), deoxyribonucleotide
triphosphates (dNTPs) (0.2 mol l-3) (Promega, UK) and
200U M-MLV reverse transcriptase (Promega, UK).
Reverse transcriptase activity was stopped by heating sam-
ples at 65°C for 10 minutes. Control RNA samples, in
which no reverse transcriptase was added, were included
to confirm that no genomic DNA contamination was
present.
Semi-quantitative PCR
0.5–1 μl of this 20 μl reaction was then used in the subse-
quent PCR. The PCR reaction was performed in a final vol-
ume of 50 μl containing 1.5 mol l-3 MgCl2, 20 mol l-3 Tris-
HCl, 50 mol l-3, KCl pH 8.3 (Promega, UK), 1.25 U Taq
DNA polymerase (Promega., UK), 40 mol l-6 dNTPs and
10 mol l-12 of each sense and antisense primer. cDNA
amplification was carried out by an initial denaturation
step of 5 minutes at 95°C followed by 34 cycles of dena-
turation at 94°C for 20 s, annealing at 57°C for 45 s and
elongation at 72°C for 45 s, followed by a final extension
step at 72°C for 10 minutes. 10 μl of each PCR product
was then separated by gel electrophoresis on 1–1.5% (w/
v) agarose gels. Products were separated alongside a 100
bp DNA molecular weight ladder (Promega, UK) for siz-
ing. The oligonucleotides synthesised (MWG, Ebersberg,
Germany) to PCR amplify the genes of interest were:
ARHGEF1 Sense 5'-AGCGAGTTCAAGAACCTGGA-3'
Antisense 5'-TCGTATATCTGGGCCTCCTG-3' [Genbank:
NM_198977]
ARHGEF11 Sense 5'-GTCTCGAAAGGCAGAGAACG-3'
Antisense 5'-ATCCTTGCCCACTGTATGCT-3' [Genbank:
NM_198236]
ARHGEF12 Sense 5'-GGAGCATCTGGGAATATGGA-3'
Antisense 5'-TCTTGCAGCTGAGGAATGTG-3' [Genbank:
NM_015313]
ARHGAP5 Sense 5'-TCCCCCATCCTATACCATCA-3'
Antisense 5'-CAGGCATTTGCTTCTGTTCA-3' [Genbank:
NM_001173]
ARHGAP24 Sense 5'-GGGCAACAGCAGCAACCACA-3'
Antisense 5'-TCGCTCGGCATTTCGCATTTTTAT-3' [18]
ARHGDIA Sense 5'-CATCCAGATCCAGGAGC-3'
Antisense 5'-GACTTGATGCTGTAGCTGCC-3' [30]
MSN Sense 5'-CTGATGGAGAGGCTGAAGCA-3'
Antisense 5'-TCTTGGACTCATCTCTGGCA-3' [31]
ACTB Sense: 5'-CAACTCCATCATGAAGTGTGAC-3',
Antisense 5'-GCCATGCCAATCTCTCATCTTG-3' [Gen-
bank: M10277]
Real-time fluorescence PCR using ABI Prism 7000 
technology
Real-time PCR was performed on a 1/125 dilution of each
the 7 PNL and 7 PL myometrial cDNA in triplicate for
each transcript, using the Applied Biosystems ABI Prism
7000 sequence Detection System (ABI, USA). The PCR
reactions were performed in a final volume of 25 μl con-
taining 12.5 μl Sybr Green PCR Master Mix (ABI, USA), 5
μl diluted cDNA and 0.4 μM of each sense and antisense
primer. The final volume of 25 μl was achieved using PCR
grade water (Sigma-Aldrich, Ireland). cDNA amplification
was performed by an initial step of 50°C for 2 minutes an
initial denaturation step at 95°C for 10 minutes, followed
by 40 cycles of denaturation at 95°C for 15 seconds,
annealing at 60°C and elongation at 72°C for 30 seconds
each. The sequences of the real time fluorescence RT-PCR
oligonucleotide primers for the genes are as above, except
ARHGEF12  and  ARHGDIA, as alternative primers for
these genes were utilised for the real time assay:
ARHGEF12 Sense 5'-TGTTGGTGACTCTCGGTTCA-3'
Antisense 5'-CCAATGAGTGGCACACAGTCT-3' [32]
ARHGDIA Sense 5'-CAGGAAAGGCGTCAAGATTG-3'
Antisense 5'-GTCAGGAACTCGTACTCCTC-3' [33]Reproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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Fluorescence data was acquired at the end of each PCR
cycle. Melting curve analysis was performed by an initial
denaturation step of 95°C for 15 seconds, cooling to
60°C for 10 seconds, and 72°C for 15 seconds. Fluores-
cence was measured continually during the melting curve
cycle. The mean Cycle Threshold (Ct) of each gene for
every patient (performed in triplicate) from their standard
curves was normalised to the corresponding mean Ct
value of β-Actin (ACTB), Gene Ct values/ACTB Ct values).
β-Actin is a housekeeping gene, it is constitutively
expressed and is used to normalise mRNA levels between
different samples. The normalised Ct values of the 7 PL
and the 7 PNL myometrial tissue types (PL v PNL) were
analysed using the independent samples t test. Results
were expressed as mean normalised Ct units ± the stand-
ard error of the mean (SEM). A P value of < 0.05 was con-
sidered to be statistically significant. Relative fold changes
were then calculated using the difference in the mean nor-
malised Ct values (x) between the pregnant at-term and
the labouring myometrium for each transcript, Relative
fold change = 2x. All statistical analysis was performed
using the SPSS statistical package using one way ANOVA
with Tukey's post hoc analysis (Statistical Package for the
Social Sciences, v.11, SPSS Inc., Chicago, IL, USA) and
GraphPad Prism version 4 (GraphPad Software Inc., San
Diego, CA, USA). Real time fluorescence RT-PCR products
were gel electrophoresed, bands extracted, purified with
the Qiaquick Gel Extraction kit (Qiagen, UK) and DNA
sequence verified (MWG, Germany).
Protein isolation
Human myometrial tissue was homogenised in ice-cold
buffer containing 1% Triton-X (Sigma-Aldrich, Dublin,
Ireland) and 0.1% sodium dodecyl sulphate (w/v) (SDS)
(Sigma-Aldrich, Ireland). Cellular debris was removed by
centrifugation at 10,000 × g, 4C for 15 minutes. The
resultant supernatant was used for Western blot analysis.
Human myometrial tissue or myometrial smooth muscle
cells or Hela cells were homogenised in Protein lysis
buffer: 50 mM Tris pH 7.4, 100 mM NaCl, 5 mM MgCl2,
0.1% Triton X-100, 10% glycerol with inhibitors (10 μg/
ml leupeptin, 10 μg/ml aprotinin, 1 mM PMSF) ice-cold
buffer (Sigma-Aldrich, Ireland). Cellular debris was
removed by centrifugation at 10,000 × g, 4°C for 15 min-
utes. The resultant supernatant was used for Western blot
analysis. Protein concentrations were determined using
the BCA protein assay reagent kit (Pierce Technology,
Rockford, Illinois, USA) as per the manufacturer's proto-
col, with bovine serum albumin as a standard.
Western blot analysis
Protein samples (30 μg) were heated at 95°C for 5 min-
utes after addition of an equal volume of 2X sample buffer
containing: 62.5 mol l-3  Tris pH 6.8, 2% SDS (w/v)
(Sigma-Aldrich, Ireland), 10% glycerol (v/v) (BDH,
Alkem Chemical Ltd, Dublin, Ireland), 5% 2-β mercap-
toethanol w/v (Sigma-Aldrich, Ireland) or 5X Laemmli
containing 50 mM DTT. This preparation was resolved by
electrophoresis on 4–20% (Pierce Technology, USA) or
12% SDS (w/v) polyacrylamide gel electrophoresis (SDS-
PAGE) gel at 100 V, room temperature for 60 minutes
(BioRad, Hercules, CA, USA) in a buffer containing 25
mol l-3 Tris base, pH 8.3, 19.2 mol l-2 glycine, and 0.1%
(w/v) SDS. The separated proteins were transferred to 0.2
μm nitrocellulose or PVDF membranes at a constant volt-
age of 100 V at 4C for 60 minutes in transfer buffer con-
taining 25 mol l-3 Tris base, 192 mol l-3 glycine, and 20%
methanol (v/v), high-performance liquid chromatogra-
phy (HPLC) grade (Sigma-Aldrich, Ireland). To ensure
transfer and equal loading of proteins, blots were stained
with Ponceau S solution (Sigma-Aldrich, Ireland) for 5
minutes, followed by washing with de-ionised water,
rapid immersion with agitation in 0.1 mol l sodium
hydroxide (Sigma-Aldrich, Ireland), and finally washing
under flowing de-ionised water for 3 minutes. Mem-
branes were incubated for 1 hour at room temperature
with phosphate-buffered saline (PBS; 1 mol l-2 phosphate
buffer, 2.7 mol l-3 potassium chloride, and 1.37 mol l-1
sodium chloride, pH 7.4) containing 0.05% Tween 20 (v/
v) (Sigma-Aldrich, Ireland) and 5% low-fat milk powder
(w/v) (Dawn Dairies, Westmeath, Ireland) to block non-
specific binding. Blots were either incubated for 60 min-
utes at room temperature or overnight at 4°C, with 1:200
dilution FilGAP antibody or a 1:100 dilution of
p115RhoGEF (H-165) sc-20804, 1:100 dilution LARG
(H-70) sc-25638, 1:100 dilution p190B RhoGAP (H-160)
sc-30206) or 1:750–1000 dilution of RHOGDI (ARHG-
DIA) (A20 sc360 Santa Cruz Biotechnology, Inc, Heidel-
berg, Germany) rabbit polyclonal IgG anti-human
primary antibodies or 1:100 dilution PDZ-RhoGEF (N-14
sc-46234), 1:1000 dilution of MSN (C-15 sc 6410), or
1:1000 dilution of p-MSN (Thr 558 sc 12895) goat poly-
clonal IgG anti-human primary antibodies (Santa Cruz
Biotechnology, Germany), or with a 1:5000–15,000 dilu-
tion of β-actin (ACTB) mouse monoclonal antibody clone
number AC-15 (Sigma-Aldrich, Ireland), diluted in PBS
containing 3% bovine serum albumin (w/v) or 5% low-
fat milk powder (w/v) (Dawn Dairies, Ireland), 0.03%
Tween 20 (v/v) and 0.1% NaN3 (v/v). Blots were then
washed three times with PBS-0.03%T for 10 minutes each
and incubated in a 1:4,000 dilution of a rabbit anti-goat
horseradish peroxidase-conjugated antibody (DakoCyto-
mation Ltd, Cambridgeshire, UK) or 1:1000 dilution anti-
rabbit secondary (Pierce Technology, USA) or 1:4000
swine anti-rabbit IgG horseradish peroxidase-conjugated
antibody (P-0217 DakoCytomation Ltd, Cambridgeshire,
UK) or in 1:4000 dilution of a goat anti-mouse horserad-
ish peroxidase-conjugated antibody (sc2005 Santa Cruz
Biotechnology, Germany) or 1:1000 anti-mouse second-
ary (Pierce Technology, USA) in 1X PBS, 3%BSA (w/v),Reproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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0.05% Tween 20 (v/v) or in 1X PBS, 5% low-fat milk pow-
der (w/v) (Dawn Dairies, Ireland) with 0.05% Tween 20
for 1 hour at room temperature. Blots were then washed
with PBS-0.05%T. Bound secondary antibody was
detected using the West-Pico chemiluminescent detection
kit as per the manufacturer's protocol (Pierce Technology,
USA) or Immobilon Western chemiluminescent HRP sub-
strate (Millipore, USA). The membranes were scanned
with the fluorescence imager (FluorchemTM 8900, Alpha
Innotech Corporation, San Leandro, California, USA) and
AlphaEaseFC software was used to detect the signal, the
image was processed and protein expression levels where
possible, were determined by densitometric analysis com-
pared to corresponding levels of the housekeeping pro-
tein,  β-Actin (ACTB). Statistical analysis of the
densitometric data (one way ANOVA and Tukey's post
hoc analysis) and graph construction were performed
using GraphPad Prism version 4 (GraphPad Software Inc.,
USA).
Immunofluorescence microscopy
Primary myometrial cells (to passage 8) were cultivated
on LabTekII 8 well chamber slides (Nalge Nunc Int.,
Naperville, IL, USA) overnight. The samples were fixed in
4% paraformaldehyde (w/v) for 30 minutes at room tem-
perature and blocked in 1X PBS, 0.01% Triton X-100 (v/v)
and 5% serum (v/v) (donkey or goat). Cells were subse-
quently incubated with primary antibody in blocking
solution, either a 1:50 dilution of MSN (C-15 sc 6410)
goat polyclonal IgG anti-human primary antibody, p-
MSN (Thr 558 sc12895) goat polyclonal IgG anti-human
primary antibody or RHOGDI (ARHGDIA) (A20 sc360)
rabbit polyclonal IgG anti-human primary antibody
(Santa Cruz Biotechnology, Germany) in PBS/1%BSA
overnight at 4°C. Samples were rinsed in 1XPBS 3 times
and incubated with Alexa Fluor 488 donkey anti-goat IgG
(A11055) or Alexa Fluor 488 goat anti-rabbit IgG
(A11070) (Molecular Probes, Eugene, OR, USA) for 1
hour at room temperature and then rinsed in PBS. Con-
trol cells were incubated with the secondary antibody
alone. After washing the coverslips were mounted on glass
slides with Vectashield mounting medium with DAPI
(Vector Laboratories, Burlingame CA, USA). Fluorescent
images were obtained using the Laser Scanning Micro-
scope LSM 510 (confocal microscope) (Carl Zeiss AG,
Strasse 22, Oberkocken, Germany) and the DP70 fluores-
cence microscope (Olympus, Tokyo, Japan).
Results
RHOGTPase regulator mRNA expression in human 
myometrium
Semi-quantitative RT-PCR
RT-PCR analysis using DNA-free™ treated RNA demon-
strated expression of ARHGEF1, ARHGEF11, ARHGEF12,
ARHGAP5, ARHGAP24 and ARHGDIA mRNA in human
non-pregnant (NP), pregnant non-labouring (PNL) and
labouring (PL) myometrium (Figure 1a–f). The absence of
transcripts in reverse transcriptase negative reactions (RT-
) confirmed that all products were RNA derived and not
generated from contaminating genomic DNA.
Real-time fluorescence RT-PCR
Relative quantitative expression analysis was then per-
formed on the seven genes ARHGEF1,  ARHGEF11,
ARHGEF12, ARHGAP5, ARHGAP24, ARHGDIA and MSN
by real-time RT-PCR. In order to minimise any undue
Representative RT-PCR gel pictures of (a) ARHGEF1, (b)  ARHGEF11, (c) ARHGEF12, (d) ARHGAP5, (e) ARHGAP24 and  (f) ARHGDIA mRNA expression in non-pregnant (NP), preg- nant non-labouring (PNL) and pregnant labouring (PL) human  myometrium Figure 1
Representative RT-PCR gel pictures of (a) ARHGEF1, (b) 
ARHGEF11, (c) ARHGEF12, (d) ARHGAP5, (e) ARHGAP24 and 
(f) ARHGDIA mRNA expression in non-pregnant (NP), preg-
nant non-labouring (PNL) and pregnant labouring (PL) human 
myometrium. Corresponding ACTB expression for each gene 
is presented underneath each gel. The DNA marker 100 bp 
ladder (Promega, UK) is indicated (M) and sizes of PCR prod-
ucts presented.
(a) ARHGEF1 311bp
ACTB 377bp
(b) ARHGEF11 301bp
ACTB
(c) ARHGEF12 215bp
ACTB
(d) ARHGAP5 425bp
ACTB
(e) ARHGAP24 216bp
ACTB
(f) ARHGDIA mRNA 435bp
ACTB
MN P P N L P L
NP PNL PL
MN P P N L P L
NP PNL PL
MN P P N L P L
MP N L P N L P LP L
PNL PNL PL PL MReproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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experimental error from sources such as pipetting inaccu-
racies, analysis of each gene was performed in triplicate.
RT-PCR product specificity was confirmed using melting
curve analysis. Amplification curve crossing points were
determined for each gene generated within the initial
phase of exponential amplification, per 0.5 μg total RNA
in the tissues studied. The mean Ct values for each tran-
script normalised to β-Actin (per 0.5 μg total RNA), were
then averaged and values determined for both labouring
(PL, n = 7) and non-labouring myometrium (PNL, n = 7).
The mean β-Actin normalised Ct values for PL and PNL ±
SEM, respectively for the 7 genes were: ARHGEF1 26.77 ±
0.23, 26.79 ± 0.6; ARHGEF11 33 ± 0.44, 33.58 ± 0.94,
ARHGEF12 29.55 ± 0.48, 29.95 ± 0.67, ARHGAP5 27 ±
0.51, 27.46 ± 0.54, ARHGAP24 28.9 ± 0.19, 29.82 ± 0.25,
ARHGDIA 27.08 ± 0.46, 27.29 ± 0.67 and MSN 29.09 ±
0.41, 28.5 ± 0.75 which is graphically represented in Fig-
ure 2. Relative fold changes were then calculated using the
difference in the Ct values (x) between the PL and PNL
myometrium for each transcript, Relative fold change = 2x.
ARHGAP24 showed the greatest fold change increase at
labour, by real-time RT-PCR which was significant (1.84-
fold increase P  = 0.0126) in comparison to the non-
labouring at-term myometrium. ARHGEF11, ARHGEF12,
ARHGAP5,  ARHGDIA  and  ARHGEF1  showed slight
increases in mRNA expression at labour, none of which
were significant. A slight decrease in MSN expression at
labour was also observed, which was not significant. A
summary of the fold changes observed using real-time flu-
orescence RT-PCR is presented in Figure 3.
RHOGTPase regulator expression in myometrial smooth 
muscle cells
RT-PCR analysis demonstrated expression of ARHGEF1,
ARHGEF11,  ARHGEF12, ARHGAP5,  ARHGAP24  and
MSN mRNA in human myometrial smooth muscle cells,
that were sub-passaged from primary cells in culture (Fig-
ure 4a(i–vi)).
Western Blot analysis demonstrated expression of pMSN
and ARHGDIA proteins in the human myometrial
smooth muscle cells (Figure 4b(i–ii)).
RHOGTPase regulator protein expression in human 
myometrium
RHOGEF, RHOGAP and RHOGDI protein expression in human 
myometrium
Protein expression of ARHGEF1, ARHGEF11, ARHGEF12,
ARHGAP24 and ARHGDIA by western blotting was dem-
onstrated in human myometrium (Figures 5, 6, 7 and 8).
Bands of approximately the correct size of 115, 171, 230,
190, 80 and 27 kDa were obtained for ARHGEF1,
ARHGEF11, ARHGEF12, ARHGAP5, ARHGAP24 and
ARHGDIA respectively, in the myometrium. ARHGAP24
expression was previously demonstrated in HeLa cells
[20] and these were used as a positive control for the west-
ern blot experiments in human myometrium. HeLa cell
lysate was also used in the other western blots, with
expression of ARHGEF1, ARHGEF11, ARHGEF12,
ARHGAP5, ARHGAP24 and ARHGDIA protein reported
in this cancer cell line. The mean β-Actin normalised den-
sitometric units ± SEM for ARHGAP24 were PL (n = 4)
0.4902 ± 0.095, PNL (n = 4) 0.389 ± 0.044 and NP (n = 4)
0.5751 ± 0.089 (Figure 5). From the densitometric analy-
ses therefore, there was a decrease in ARHGAP24 protein
expression at PNL in comparison to NP and there was an
increase in protein expression at PL in comparison to
PNL.
There was no significant difference however in ARHGEF1
expression in myometrial NP, PNL or PL after Western
blot densitometric analysis (Figure 6). The averaged β-
Actin normalised densitometric units ± SEM for
ARHGEF1 were PL (n = 4) 0.2055 ± 0.0303, PNL (n = 4)
0.2315 ± 0.015 and NP (n = 4) 0.251 ± 0.015 (Figure 6).
The mean β-Actin normalised densitometric units ± SEM
for ARHGDIA were PL (n = 4) 0.142 ± 0.023, PNL (n = 4)
0.1541 ± 0.008 and NP (n = 4) 0.2561 ± 0.049 (Figure 7).
From the densitometric data there was a decrease in ARH-
GDIA expression at PNL and PL in comparison to NP, and
where both PNL and PL expression was similar. None of
these results however, were significant.
The expression of ARHGEF11, ARHGEF 12 and ARHGAP5
protein was detected however the western blots were not
suitable to perform densitometric analysis as expression
was weak in some cases with some background on the
blots (Figure 8a,b and 8c). Also, the expression of
ARHGEF1, 11, 12 and ARHGAP5 was much weaker in the
myometrium in comparison to that in the HeLa cells. Two
protein bands were visible for ARHGEF11 both in the
HeLa cells and in the myometrial tissue samples (Figure
8a). The doublet in the HeLa cells ran higher than those in
the myometrial samples possibly due to differences in
posttranslational modification or perhaps due to differ-
ences associated with the cancer cell line. The lower band
in the myometrial samples corresponds most closely to
the expected size of 167–171 kDa for human ARHGEF1.
ARHGEF12 protein expression was also observed with a
band of the expected size of 220–230 kDa with an
observed increase in expression in PNL and PL in compar-
ison to NP (Figure 8b).
ARHGAP5 expression was also detected in all the myome-
trial biopsies examined, with a difference in size, with the
HeLa protein band being shifted down the gel, possibly
due to alternative posttranslational modifications or a
truncated ARHGAP5 version in the cancer cell line (Figure
8c). The band in the myometrial samples appears to beReproductive Biology and Endocrinology 2008, 6:1 http://www.rbej.com/content/6/1/1
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Graphical representations of real-time fluorescence RT-PCR results of β-Actin normalised Ct values plotted against myome- trial pregnancy state (PL n = 7 and PNL n = 7) for each of the genes ± SEM (indicated by the error bars):ARHGEF1, ARHGEF11,  ARHGEF12, ARHGAP5, ARHGAP24, ARHGDIA and MSN Figure 2
Graphical representations of real-time fluorescence RT-PCR results of β-Actin normalised Ct values plotted against myome-
trial pregnancy state (PL n = 7 and PNL n = 7) for each of the genes ± SEM (indicated by the error bars):ARHGEF1, ARHGEF11, 
ARHGEF12, ARHGAP5, ARHGAP24, ARHGDIA and MSN. Lower PL Ct values correspond to increased levels of mRNA expres-
sion for each gene at PL, in comparison to PNL.
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closer in size to that predicted (190 kDa) for human
ARHGAP5.
MSN protein expression in human myometrium
Western blotting analysis demonstrated MSN protein
expression (78 kDa band) in human NP, PL and PNL
myometrium (Figure 9a). Phosphorylated moesin or
active moesin, p-MSN, protein expression was also
observed in NP, PNL, PL and in PT myometrium (Figure
9b and Figure 10a and 10b). No significant difference in
p-MSN protein band intensity was evident between the
myometrial biopsies (PL v PNL) or (PT v PL), after densi-
tometric analysis (Figure 10a and 10b). The mean β-Actin
normalised densitometric units ± SEM for p-MSN (PL v
PNL) (Figure 10a) were PL (n = 3) 0.853 ± 0.017, PNL (n
= 3) 0.947 ± 0.076 and for p-MSN (PT v PL) densitometry
(Figure 5d) PT (n = 3) 0.353 ± 0.089, PL (n = 3) 0.167 ±
0.023 (Figure 10b). Summarising the densitometric data
there was a decrease in p-MSN band intensity at PL in
comparison to PNL, though this was not significant (Fig-
ure 10a). Also there was a slight increase in p-MSN band
intensity in the PT myometrium, in comparison to the PL
tissue, though this also was not significant (Figure 10b).
ARHGDIA and MSN immunolocalisation in human 
myometrial smooth muscle cells
Immunolabelling confocal microscopy localised ARHG-
DIA protein to the cytoplasm of human myometrial
smooth muscle cells (Figure 11a (i) and (ii)). MSN and
pMSN immunofluorescence studies localised the proteins
to vesicle structures in the cytoplasm of the myometrial
smooth muscle cells (Figure 11c and 11d).
a. Representative RT-PCR gel pictures of (i) ARHGEF1 (ii)  ARHGEF11 (iii) ARHGEF12 (iv) ARHGAP5 (v) ARHGAP24 and  (vi) MSN mRNA expression in human myometrial cells (lanes  1 and 2 of each gel and lanes 2–3 for MSN) Figure 4
a. Representative RT-PCR gel pictures of (i) ARHGEF1 (ii) 
ARHGEF11 (iii) ARHGEF12 (iv) ARHGAP5 (v) ARHGAP24 and 
(vi) MSN mRNA expression in human myometrial cells (lanes 
1 and 2 of each gel and lanes 2–3 for MSN). The PCR nega-
tive control is indicated (C). The DNA marker 100 bp ladder 
(Promega, UK) is indicated (M). b. Representative western 
blots of (i) p-MSN and (ii) ARHGDIA protein expression in 
human myometrial cells (lanes 1–4 of each gel). The corre-
sponding β-Actin (ACTB) western blot is presented under-
neath the appropriate blot. Molecular weights are indicated 
in kDa.
A
(i) ARHGEF1
(ii) ARHGEF11
(iii) ARHGEF12
(iv) ARHGAP5
(v) ARHGAP24
(vi) MSN mRNA 574bp
B
(i) p-MSN protein ~77kDa
ACTB
(ii) ARHGDIA ~30kDa
ACTB
M1 2
12 C M
M1 2
12 C M
M1 2
M123
123 4
12 34
A summary of the fold changes for each gene at labour (n =  7) in comparison to the non-labouring state (n = 7) in human  myometrium, normalised to β-Actin, from real-time fluores- cence RT-PCR analyses Figure 3
A summary of the fold changes for each gene at labour (n = 
7) in comparison to the non-labouring state (n = 7) in human 
myometrium, normalised to β-Actin, from real-time fluores-
cence RT-PCR analyses. Fold change at labour is plotted 
against gene name: ARHGEF1, ARHGEF11, ARHGEF12, 
ARHGAP5, ARHGAP24, ARHGDIA and MSN, respectively. An 
asterisk indicates P < 0.05.
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Discussion
It is now established that RHOA, B and D and RND mol-
ecules of the RHOGTPase subfamily of RAS proteins are
involved in the regulation of myometrial function during
pregnancy and labour. Regulation of these myometrial
GTPases is therefore essential, at this critical time.
We have determined that some RHOGTPase regulators,
ARHGEF1, ARHGEF11, ARHGEF12, ARHGAP5,
ARHGAP24, ARHGDIA and MSN are expressed in human
myometrium during pregnancy, labour and in the non-
pregnant state. Their expression was also detected in the
smooth muscle cells of this tissue. All three RHOGEFs,
ARHGEF1, ARHGEF11, ARHGEF12 were previously
reported in vascular smooth muscle and exhibited very
selective activation of RHOA [13,34,35]. ARHGEF1
mRNA or protein expression did not significantly alter in
the myometrium at term pregnancy, at labour or in the
non-pregnant state.
ARHGEF11 has the ability to induce calcium sensitisation
in rabbit pulmonary artery smooth muscle [14]. Further-
more, ARHGEF11 myometrial mRNA expression was
reported to be up-regulated after estradiol treatment of
ovariectomised guinea pigs [15]. However ARHGEF11
mRNA expression did not vary in the pregnant human
myometrium. Moreover, the expression of ARHGEF11
protein was weaker in all the myometrial samples ana-
lysed, in comparison to the HeLa cells. ARHGEF12 mRNA
and protein expression was detected in human myo-
metrium and on the myometrial smooth muscle cells.
However, no significant difference in gene expression was
observed between the myometrial samples at the different
time-points.
The expression of two RhoGTPases, ARHGAP5 and
ARHGAP24 was observed in human myometrium and on
myometrial smooth muscle cells, with a significant 1.84-
fold increase in ARHGAP24 mRNA and a slight increase in
protein expression at labour in comparison to the non-
labouring state. In vascular smooth muscle cells it has
been determined that ARHGAP24 is a key regulator of
angiogenesis, where it displays GTPase activity to RHO
[18]. It is also known that it acts as a GTPase activator for
RAC by converting it to an inactive GDP bound state. It
controls actin remodelling by inactivating RAC, down-
stream of Rho [19]. ARHGAP24 can also suppress RAC
Representative Western blot of ARHGEF1 expression in  samples of PL (n = 4), PNL (n = 4) and NP (n = 4) human  myometrium, and HeLa cells (H) Figure 6
Representative Western blot of ARHGEF1 expression in 
samples of PL (n = 4), PNL (n = 4) and NP (n = 4) human 
myometrium, and HeLa cells (H). The corresponding ACTB 
protein expression is presented underneath. Protein bands of 
interest are indicated with arrows and molecular weights are 
indicated in kDa. Quantitative densitometric analysis of the 
western blot is presented, with β-Actin normalised densito-
metric units for each protein plotted against pregnancy state 
± SEM (indicated with error bars).
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Representative Western blot of ARHGAP24 expression in  samples of PL (n = 4), PNL (n = 4) and NP (n = 4) human  myometrium, and HeLa cells (H) Figure 5
Representative Western blot of ARHGAP24 expression in 
samples of PL (n = 4), PNL (n = 4) and NP (n = 4) human 
myometrium, and HeLa cells (H). The corresponding ACTB 
protein expression is presented underneath. Protein bands of 
interest are indicated with arrows and molecular weights are 
indicated in kDa. Quantitative densitometric analysis of the 
western blot is presented, with β-Actin normalised densito-
metric units for each protein plotted against pregnancy state 
± SEM (indicated with error bars).
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and CDC42 in vitro, and its over-expression induces cell
rounding with disruption of actin stress fibres and forma-
tion of membrane ruffles, lamellipodia and filopodia
[20]. The observed increase in ARHGAP24 expression at
labour in the myometrium may result in the inhibition of
RHOGTPases, perhaps RAC and CDC42 or others, per-
haps resulting in the alteration of uterine smooth muscle
contractility at labour.
ARHGAP5 or p190B-RhoGAP as it is also known, is ubiq-
uitously expressed and it has previously been established
that it displays specificity for RHOA, RAC and CDC42
[8,36]. Recruitment of it's isoform, p190-RHOGAP is
associated with RHOA inactivation and inhibition of con-
tractility in rat vascular smooth muscle cells [21].
ARHGAP5 myometrial mRNA expression was not signifi-
cantly different at term pregnancy or at labour. ARHGAP5
protein expression was demonstrated in human myo-
metrium and mRNA expression determined on myome-
trial smooth muscle cells.
RHOGDIs are also thought to play an important role in
regulating the association of RHOGTPases with cell mem-
brane compartments. This is based on their ability to
mask the prenyl group of post-translationally modified
GTPases, thereby inhibiting the interaction of these
GTPases with membranes [9]. ARHGDIA can bind to
RHOA and B, RAC1 and 2, and CDC42 and therefore
result in their inhibition by binding to these RHOGTPases
and maintain them in the cytosol [23]. We observed ARH-
GDIA  mRNA and protein expression in human myo-
metrium at term labour, at labour and in the non-
pregnant state and also in human myometrial smooth
muscle cells. A decrease in its protein expression at labour
and at term pregnancy, in comparison to the non-preg-
nant state, suggests decreased RHOGDI expression may
result in increased RHOGTPase activation observed dur-
ing pregnancy and labour [4-6] by being unable to bind to
the RHOGTPases in the cytosol. Immunofluorescent con-
focal microscopy localised ARHGDIA protein to the cyto-
plasm of myometrial smooth muscle cells. The decrease in
expression of ARHGDIA at labour and at the end of preg-
nancy may result in the decrease of its inhibitory effect on
RHOGTPases either RHOA or RHOB or other RHOGT-
Pases, thus enabling them to be activated by RHOGEFs.
Although RHOGEFs have received much attention as key
players in GTPase activation, there is also evidence to sug-
Representative Western blots of (a) ARHGEF11 (b)  ARHGEF12 (c) ARHGAP5 expression in samples each of  pregnant labouring (PL, n = 4) pregnant non-labouring (PNL,  n = 4) and non-pregnant (NP, n = 4) human myometrium,  and HeLa (H) cells Figure 8
Representative Western blots of (a) ARHGEF11 (b) 
ARHGEF12 (c) ARHGAP5 expression in samples each of 
pregnant labouring (PL, n = 4) pregnant non-labouring (PNL, 
n = 4) and non-pregnant (NP, n = 4) human myometrium, 
and HeLa (H) cells. The corresponding ACTB protein 
expression is also presented. Protein bands of interest are 
indicated with arrows and molecular weights are indicated in 
kDa.
Representative Western blot of ARHGDIA expression in  samples of PL (n = 4), PNL (n = 4), NP (n = 4) human myo- metrium, and HeLa cells (H) Figure 7
Representative Western blot of ARHGDIA expression in 
samples of PL (n = 4), PNL (n = 4), NP (n = 4) human myo-
metrium, and HeLa cells (H). The corresponding ACTB pro-
tein expression is presented. Protein bands of interest are 
indicated with arrows and molecular weights are indicated in 
kDa. Quantitative densitometric analysis of the western blot 
is presented, with β-Actin normalised densitometric units for 
each protein plotted against pregnancy state ± SEM (indi-
cated with error bars).
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gest that RHOGAPs and RHOGDIs may play a role in the
activation of the RHOGTPase cycle and do not just deacti-
vate or inhibit GTPases. For example, the interaction
between RHOGDI and RHO can be inhibited by binding
of RHOGDI to members of the ERM family, that serve as
crosslinkers between actin filaments and the plasma
membrane [27]. The modulation of ERM protein activity
therefore may contribute to the activation of GTPases, pre-
sumably by sequestering RHOGDI [37].
The expression of the ERM, MSN was observed for the first
time in this study in the human myometrium, and its
expression demonstrated in human myometrial smooth
muscle cells. Activated or phosphorylated MSN protein
was also observed in the smooth muscle cells. This key
protein can cross-link the cortical actin cytoskeleton to
plasma membrane protein, regulating cell motility and
(a) Representative Western blot analysis of p-MSN expres- sion with corresponding ACTB blot, in PL (n = 3) and PNL (n  = 3) human myometrium Figure 10
(a) Representative Western blot analysis of p-MSN expres-
sion with corresponding ACTB blot, in PL (n = 3) and PNL (n 
= 3) human myometrium. Densitometric analysis of the 
above p-MSN protein expression normalised to ACTB is also 
presented, with normalised densitometric units plotted 
against pregnancy state. (b) Representative Western blot 
analysis of p-MSN protein expression with corresponding 
ACTB blot, in PT (n = 3) and PL (n = 3) human myometrium. 
Densitometric analysis of the above p-MSN protein expres-
sion normalised to ACTB is also presented, with normalised 
densitometric units plotted against pregnancy state.
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(a) Representative western blot of MSN protein expression  (indicated with an arrow) in non-pregnant (NP), pregnant  non-labouring (PNL) and pregnant labouring (PL) human  myometrium Figure 9
(a) Representative western blot of MSN protein expression 
(indicated with an arrow) in non-pregnant (NP), pregnant 
non-labouring (PNL) and pregnant labouring (PL) human 
myometrium. The corresponding ACTB expression is also 
presented. (b) Representative western blot of p-MSN protein 
expression (indicated with an arrow) in non-pregnant (NP), 
pregnant non-labouring (PT) and pregnant labouring (PL) 
human myometrium. Corresponding ACTB expression is 
presented underneath the blot.
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adhesion and is also a RHO downstream effector. This
molecule therefore, serves an important function in all
cells, enabling cell adhesion and actin cytoskeletal move-
ment of cells. Myometrial smooth muscle MSN may be
activated during contraction and thus result in the activa-
tion of RHOGTPases through the displacement of RHO
from RHOGDI.
RHOGTPases play many significant roles in the body and
none more so than in the myometrium during pregnancy
and labour. Regulation of these molecules is vital as any
error in their control could have serious consequences,
such as in preterm labour. The expression of the various
RHOGEFs, RHOGAPs, a RHOGDI and MSN in the
human myometrium and the increase in ARHGAP24
expression at labour suggests a complex RHO regulatory
mechanism exists in this tissue which may play a role in
the control of myometrial contractility. Further investiga-
tion however, is necessary to fully elucidate the biochem-
ical pathways involved.
Conclusion
This study demonstrated the expression of ARHGEF1,
ARHGEF11, ARHGEF12, ARHGAP5, ARHGAP24, ARHG-
DIA and MSN in human myometrium, at term pregnancy,
at labour, in the non-pregnant state and in myometrial
smooth muscle cells. It was also determined that
ARHGAP24 mRNA expression significantly increased at
labour. These data demonstrate the expression of
RHOGTPase regulatory molecules in the myometrium
and suggest some may play a role in the control of con-
tractility in this tissue at labour.
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